Research summary ·
Attributable Fraction of Epstein-Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta-Analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This was a systematic review and meta-analysis of Epstein-Barr virus, or EBV, in lymphoma. EBV is a known cancer-causing virus. The authors pooled how often tumors tested positive for EBV. They did this for each lymphoma subtype. They split the results by HIV status and region. The studies ran from 1990 to 2024.
What they found
307 studies with more than 21,140 lymphoma cases were included. In people without HIV, EBV was found most often in extranodal NK/T-cell lymphoma. It was found least often in follicular lymphoma. Hodgkin, Burkitt and plasmablastic lymphoma lay between them. EBV was more common in tumors from people living with HIV. This was so for diffuse large B-cell and plasmablastic lymphoma. Burkitt lymphoma was the only subtype with rates that differed by region. Nearly all East African Burkitt tumors were EBV positive.
What it means for patients
The authors call it the first systematic evidence of EBV's substantial role in lymphoma. They say it is especially important in lymphomas of people living with HIV. They say the data can help estimate the full burden of EBV-related disease. They say it can inform plans such as vaccines, early diagnosis or targeted therapy.
Why it is not certain yet
The rates varied by subtype, HIV status and region. Only Burkitt lymphoma showed evidence of differences by region. A pooled rate depends on the studies behind it. The abstract does not give how many studies covered each subtype.
Source
Attributable Fraction of Epstein-Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta-Analysis.
PubMed · PMID 41947331We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Burkitt lymphoma publications